Bile is a liquid produced by the liver that travels down the duodenum and helps digest fats. Cholangiocarcinoma is the abnormal growth of cells that carry bile from the liver to the duodenum and affects the patient's health and life.

The FDA has rapidly approved infigratinib (Truseltiq, QED Therapeutics) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma who have been previously treated with fibroblast growth factor fusion. strand 2 (FGFR2) or other rearrangement.